{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:35:43Z","timestamp":1791117343653,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.eururo.2006.10.005","type":"journal-article","created":{"date-parts":[[2006,10,21]],"date-time":"2006-10-21T11:11:23Z","timestamp":1161429083000},"page":"1054-1064","source":"Crossref","is-referenced-by-count":53,"title":["Efficacy and Tolerability of Tolterodine Extended Release in Male and Female Patients with Overactive Bladder"],"prefix":"10.1016","volume":"51","author":[{"given":"Roger","family":"Dmochowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Marschall-Kehrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph T.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2006.10.005_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society","volume":"61","author":"Abrams","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2006.10.005_bib2","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.eururo.2006.04.018","article-title":"The current and future burden and cost of overactive bladder in five European countries","volume":"50","author":"Reeves","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.10.005_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2006.10.005_bib4","first-page":"S580","article-title":"Overactive bladder significantly affects quality of life","volume":"6","author":"Abrams","year":"2000","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.eururo.2006.10.005_bib5","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0090-4295(01)00986-4","article-title":"Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey","volume":"57","author":"Liberman","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2006.10.005_bib6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1524-4733.2004.74008.x","article-title":"The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey","volume":"7","author":"Coyne","year":"2004","journal-title":"Value Health"},{"key":"10.1016\/j.eururo.2006.10.005_bib7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1046\/j.1464-410X.2003.04463.x","article-title":"The impact on health-related quality of life of stress, urge and mixed urinary incontinence","volume":"92","author":"Coyne","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2006.10.005_bib8","first-page":"983","article-title":"The relationship between clinical parameters and health-related quality of life as measured by the 15D in incontinent women before and after treatment","volume":"83","author":"Stach-Lempinen","year":"2004","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.eururo.2006.10.005_bib9","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1464-410X.2003.04527.x","article-title":"The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA","volume":"92","author":"Coyne","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2006.10.005_bib10","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2006.10.005_bib11","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1742-1241.2006.00986.x","article-title":"Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: The IMPACT trial","volume":"60","author":"Elinoff","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.eururo.2006.10.005_bib12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1464-410X.2005.05889.x","article-title":"Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries","volume":"97","author":"Irwin","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2006.10.005_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eururo.2005.02.024","article-title":"The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.10.005_bib14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.urology.2005.10.061","article-title":"Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia","volume":"67","author":"Rackley","year":"2006","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.eururo.2006.10.005_bib15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S1569-9056(05)80248-9","article-title":"Nighttime dosing of tolterodine reduces overactive bladder-related nocturnal frequency in patients with overactive bladder and nocturia","volume":"4","author":"Abrams","year":"2005","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2006.10.005_bib16","unstructured":"European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products. Note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence. London. December 2002. CPMP\/EWP\/18\/01."},{"key":"10.1016\/j.eururo.2006.10.005_bib17","unstructured":"Coyne KS, Matza L, Thompson C, Bavendam T, Jumadilova Z. A comparison of three approaches to analyze urinary urgency as a treatment outcome. Paper presented at: 35th Annual Meeting of the International Continence Society, August 28\u2013September 2, 2005, Montreal, Quebec, Canada."},{"key":"10.1016\/j.eururo.2006.10.005_bib18","unstructured":"Coyne KS, Matza L, Thompson C, et al. From an OAB patient perspective: health-related quality of life improves when frequency and urgency improve. Paper presented at: 35th Annual Meeting of the International Continence Society, August 28\u2013September 2, 2005, Montreal, Quebec, Canada."},{"key":"10.1016\/j.eururo.2006.10.005_bib19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/nau.10053","article-title":"The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"van Kerrebroeck","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2006.10.005_bib20","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0022-5347(05)64567-3","article-title":"Does gender or age affect the efficacy and safety of tolterodine?","volume":"168","author":"Michel","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.10.005_bib21","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.eururo.2006.02.018","article-title":"A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder","volume":"49","author":"Chapple","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.10.005_bib22","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0022-5347(05)65982-4","article-title":"Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings","volume":"166","author":"Hyman","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.10.005_bib23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/00365597909179530","article-title":"The correlation between symptoms, cystometric and urodynamic findings","volume":"13","author":"Andersen","year":"1979","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2006.10.005_bib24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/nau.10057","article-title":"Detrusor instability with equivocal obstruction: A predictor of unfavorable symptomatic outcomes after transurethral prostatectomy","volume":"21","author":"Machino","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2006.10.005_bib25","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1097\/01.ju.0000181823.33224.a0","article-title":"Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia","volume":"174","author":"Kaplan","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2006.10.005_bib26","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2004.05039.x","article-title":"Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder","volume":"94","author":"Lee","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2006.10.005_bib27","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMp068070","article-title":"The challenge of subgroup analyses\u2014reporting without distorting","volume":"354","author":"Lagakos","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2006.10.005_bib28","unstructured":"ClinicalTrials.gov Web site. A randomized, double blind, placebo controlled trial of Detrol LA in men with overactive bladder [cited July 31, 2006]. Available at: URL: http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00282932?order=3."}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283806011705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283806011705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T18:44:58Z","timestamp":1587235498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283806011705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0302283806011705"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2006.10.005","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}